# What a New Randomized Trial Found About Sativex and Appetite Hormones in Older Adults

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/sativex-randomized-trial-older-adults-appetite/
> **Published:** 2026-07-29T17:39:58-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:01:58-04:00
> **Clinical Summary:** Sativex randomized trial older adults appetite: This sativex randomized trial in older adults found no significant effect on appetite hormones or subjective

---

CED Clinical Relevance #79 Notable Clinical Interest A July 11, 2026 randomized, double-blind, placebo-controlled crossover trial directly tests a commonly extrapolated claim about cannabis-based [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) in older adults and finds no statistically significant hormonal or subjective effect, which is useful for calibrating clinical expectations even though the small sample limits certainty.

Clinical Insight | CED Clinic
Sativex has an established role in spasticity management, and its cannabinoid content makes [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) a biologically plausible secondary benefit worth testing directly rather than assuming from other populations. This trial did exactly that in a population, older adults with poor appetite, where the claim is often extended without population-specific evidence. The result was a clean, well-instrumented null finding: no significant change in GLP-1, ghrelin, or subjective appetite after a single dose. That distinction matters clinically, because a rigorously tested negative result should change how confidently clinicians recommend Sativex specifically for [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) in frail older patients.

SativexAppetiteOlder AdultsRandomized Trial[Endocannabinoid System](https://cedclinic.com/endocannabinoid-system-fear-extinction/)

Audience
Geriatric and palliative care clinicians, endocannabinoid-focused researchers, caregivers of older adults with poor appetite, and cannabis-science readers evaluating appetite-stimulant claims

Primary Topic
a randomized crossover trial testing Sativex versus placebo on appetite hormones and subjective appetite in older adults with poor appetite

Source
[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42514343/)

Table of Contents

- [Sativex and Appetite Hormones in Older Adults: What a New Randomized Trial Found](#Sativex_and_Appetite_Hormones_in_Older_Adults_What_a_New_Randomized_Trial_Found)
- [How to Read a Well-Designed Negative Cannabis Trial Without Overcorrecting](#How_to_Read_a_Well-Designed_Negative_Cannabis_Trial_Without_Overcorrecting)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame)
- [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[This Trial Does Not Prove Sativex Won’t Help You Personally](#This_Trial_Does_Not_Prove_Sativex_Won8217t_Help_You_Personally)
- [Poor Appetite in Older Adults Needs a Broader Workup](#Poor_Appetite_in_Older_Adults_Needs_a_Broader_Workup)
- [GLP-1 and Ghrelin Did Not Move as Hypothesized](#GLP-1_and_Ghrelin_Did_Not_Move_as_Hypothesized)
- [Manage Expectations Before Recommending Sativex for Appetite](#Manage_Expectations_Before_Recommending_Sativex_for_Appetite)
- [Small Samples Cut Both Ways](#Small_Samples_Cut_Both_Ways)
- [Appetite Loss in Aging Populations Remains a Real Problem](#Appetite_Loss_in_Aging_Populations_Remains_a_Real_Problem)
- [Multiple Comparisons and a Secondary Analysis Design](#Multiple_Comparisons_and_a_Secondary_Analysis_Design)
- [What Would Strengthen This Evidence](#What_Would_Strengthen_This_Evidence)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## Sativex and Appetite Hormones in Older Adults: What a New Randomized Trial Found

A July 11, 2026 randomized, double-blind, placebo-controlled crossover trial in 17 adults age 65 and older with poor appetite found no statistically significant effect of a single Sativex dose on GLP-1, total ghrelin, or subjective appetite compared with placebo. The trial is well designed but small, so it reads as an honest null result rather than proof that cannabis-based medicines cannot help appetite in this population.

What This Study Teaches Us
The trial teaches that a plausible endocannabinoid mechanism for appetite stimulation, tested rigorously in a randomized crossover design, did not produce a statistically significant hormonal or subjective effect in older adults with poor appetite after a single dose, and that dose-response associations with plasma THC also fell short of significance.

Why This Matters
Cannabis-based medicines are sometimes recommended for appetite stimulation in older adults by extrapolating from effects seen in younger or disease-specific populations. This trial tests that assumption directly in the population where it is often recommended, and finds no significant hormonal or subjective support for it after a single dose.

Study Snapshot

Study Type
Randomized, double-blind, placebo-controlled crossover trial (protocolized secondary analysis)

Population
17 adults age 65 and older with poor appetite

Intervention
Single dose of Sativex (8.1 mg THC / 7.5 mg CBD) versus placebo on two separate study days

Primary Outcomes
Postprandial GLP-1 and total ghrelin after one dose plus a standardized breakfast; subjective appetite via visual analog scale across two doses, breakfast, and an ad libitum lunch

Key Result
No statistically significant differences between Sativex and placebo for GLP-1, total ghrelin, or subjective appetite

THC/Metabolite Association
Higher plasma THC and metabolite levels trended toward lower GLP-1 and subjective appetite and higher ghrelin, but none of these associations reached statistical significance

Trial Registration
ClinicalTrials.gov NCT05503147; EudraCT 2021-002318-15

Journal
Nutrients

Published
July 11, 2026

PMID
42514343

DOI
10.3390/nu18142274

Clinical Bottom Line
This randomized crossover trial found no statistically significant effect of a single Sativex dose on GLP-1, ghrelin, or subjective appetite in older adults with poor appetite, and clinicians should not present appetite stimulation as a proven, mechanism-confirmed benefit of Sativex in this population based on this evidence.

What the Trial Actually Tested

This was a secondary analysis of a double-blind, randomized, placebo-controlled crossover trial in 17 adults age 65 and older who had poor appetite, a common problem tied to malnutrition risk in this age group.

Participants received a single dose of Sativex (8.1 mg THC and 7.5 mg CBD) or placebo on two separate visits. The investigators measured postprandial GLP-1 and total ghrelin after one dose plus a standardized breakfast, and tracked subjective appetite on visual analog scales through two doses, breakfast, and an ad libitum lunch.

What the Trial Did Not Find

Compared with placebo, Sativex produced no statistically significant difference in GLP-1 (estimated 2.38 pmol/L reduction; 95% CI -0.71 to 5.46; Bonferroni-corrected p = 0.274) or in the time course of total ghrelin (Bonferroni-corrected p = 0.054).

Subjective appetite ratings were also essentially unchanged, with a combined appetite score just 5.2 mm lower than placebo on a visual analog scale (95% CI -24.4 to 4.0; p = 1.00) and every individual appetite sensation showing a Bonferroni-corrected p value of 1.00.

Where This Deserves Skepticism

The trial enrolled only 17 participants, which is not enough statistical power to rule out a real but modest effect, and several confidence intervals were wide enough to be compatible with either a meaningful change or none at all.

Higher plasma THC and metabolite concentrations trended toward lower GLP-1 and subjective appetite and higher ghrelin, but the authors report that none of these dose-response associations reached statistical significance either, so this should not be read as evidence of a hidden dose-dependent benefit.

What This Means for Appetite Counseling

For clinicians who have offered or considered Sativex as an appetite stimulant in older, frail, or malnourished patients, this trial does not provide hormonal or subjective evidence to support that specific use.

Poor appetite in older adults is multifactorial, and this study suggests that whatever benefit patients might report anecdotally with cannabis-based medicines for appetite likely does not run primarily through acute changes in GLP-1, ghrelin, or single-dose subjective hunger ratings in this population.

How Strong Is This Evidence?
This is a randomized, double-blind, placebo-controlled crossover design, which is a strong structure for isolating a drug effect from placebo and from natural variability in appetite and hormone levels. It is also a registered trial (ClinicalTrials.gov NCT05503147; EudraCT 2021-002318-15) with pre-specified outcomes analyzed using linear mixed-effects models and Bonferroni correction for multiple comparisons. Its main limitation is size: 17 participants is a small sample for detecting a modest hormonal or appetite effect, so this trial is better read as a well-conducted negative signal than as definitive proof of no effect.

Where This Paper Deserves Skepticism
The central caution here is not that Sativex clearly does nothing for appetite hormones, but that this trial could not detect a statistically significant effect in a small sample with wide confidence intervals. Readers should resist collapsing a nonsignificant result into proof of no effect, and should also resist treating the direction of the THC/metabolite associations as if it confirmed a real dose-response relationship, since the authors explicitly report those associations did not reach significance either.

What This Paper Does Not Show
This trial does not show that Sativex or other THC/CBD combination products are ineffective for appetite stimulation in general, and it does not evaluate outcomes such as body weight, nutritional status, or longer-term repeated dosing. It also does not test other cannabis formulations, other patient populations, or oral capsule or edible routes, and a single-dose crossover design cannot capture cumulative or tolerance-related effects that might occur with sustained use.

How This Fits With the Broader Clinical Conversation

Cannabis-based medicines are sometimes proposed as appetite stimulants for older adults with malnutrition risk, extrapolating from THC’s known effects on hunger in younger or different clinical populations. This trial is one of relatively few attempts to test that extrapolation directly, using objective appetite-regulating hormones alongside subjective appetite ratings in a geriatric population.

The result fits a broader pattern in cannabis appetite research: effects that appear plausible from receptor biology and from younger or disease-specific populations do not always replicate cleanly when tested rigorously in a different population, such as older adults with age-related appetite loss rather than cachexia from cancer or HIV.

Dr. Caplan’s Take

*This is exactly the kind of trial our field needs more of: small, honest, and willing to report a null result instead of reaching for a secondary comparison that happens to clear significance. A well-designed negative trial is more useful to clinicians than an underpowered positive one, because it keeps us from overpromising a mechanism the data do not support.*

*My practical takeaway is that I would not counsel a patient that Sativex works as an appetite stimulant in older adults through GLP-1 or ghrelin based on this evidence. If a patient in this age group reports improved appetite with a [cannabis-based medicine](https://cedclinic.com/former-nfl-quarterback-urges-athletes-to-consider-cbd-products/), that may still be a real, individually meaningful effect, but this trial suggests it is not reliably explained by the hormonal pathway the investigators tested, and clinicians should keep expectations modest and grounded in this population’s evidence rather than extrapolating from younger patients.*

What a Careful Reader Should Take Away
A careful reader should conclude that this single-dose, small, randomized crossover trial did not detect a statistically significant effect of Sativex on GLP-1, total ghrelin, or subjective appetite in older adults with poor appetite, while recognizing that the sample size and wide confidence intervals leave real uncertainty rather than proof of no effect.

Evidence Interpretation Guide

## How to Read a Well-Designed Negative Cannabis Trial Without Overcorrecting

Negative trials are easy to misread in both directions. Some readers dismiss them because the sample is small, while others treat a null result as final proof that a mechanism does not exist.

A better approach is to ask what the trial’s design could and could not detect, and to separate a null finding here from a claim that no effect exists anywhere.

### A Four-Step Reading Frame

**Start With the Design’s Power**A double-blind, placebo-controlled crossover trial is a strong design, but with only 17 participants it is underpowered to detect a modest true effect, which limits how confidently a null result can be generalized.

**Separate Statistical Significance From Clinical Certainty**Wide confidence intervals around the GLP-1, ghrelin, and appetite estimates mean the true effect could be closer to meaningful or closer to none. A nonsignificant result here is not equivalent to definitive proof of no effect.

**Note What Was and Was Not Tested**This trial tested a single dose of Sativex against placebo in older adults with poor appetite. It did not test repeated dosing, other formulations, or the younger or disease-specific populations where cannabis appetite effects have been studied before.

**Translate Into Counseling, Not Prediction**The result supports caution about promising a hormonal appetite-stimulating effect from Sativex in this specific population, without ruling out that some patients may still experience a subjective benefit worth monitoring individually.

The Research Question
Does a single dose of Sativex change postprandial GLP-1, total ghrelin, or subjective appetite compared with placebo in older adults with poor appetite?

The Patient Question
If I am older and have a poor appetite, does this trial mean a [cannabis-based medicine](https://cedclinic.com/former-nfl-quarterback-urges-athletes-to-consider-cbd-products/) like Sativex will not help, or mainly that this particular study could not prove it works through these specific hormones?

The Bottom Line
The trial found no statistically significant hormonal or subjective appetite effect, but its small size means this is better read as an honest null result than as final proof the approach cannot help anyone.

CED Perspective Lens

## The Same Study Can Mean Different Things Depending on the Question Being Asked

Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.

Lens Overview
This trial reads differently depending on whether you are a patient with poor appetite, a geriatric clinician, an endocrinology-minded reader, or someone skeptical of small pharmacology trials. These lenses keep the interpretation precise rather than overstated in either direction.

#### This Trial Does Not Prove Sativex Won’t Help You Personally

If you are an older adult with poor appetite, this trial does not close the door on [cannabis-based medicine](https://cedclinic.com/former-nfl-quarterback-urges-athletes-to-consider-cbd-products/) helping you, but it also does not provide hormonal proof that it will.

The honest message is that a single dose of Sativex did not produce a measurable change in appetite hormones or appetite ratings in this small study, so any decision to try it should be made with realistic expectations and close follow-up rather than an assumption that it works like an appetite switch.

Lens takeaway
Approach Sativex for appetite as an individual trial with monitoring, not a proven hormonal intervention.

#### Poor Appetite in Older Adults Needs a Broader Workup

Poor appetite in older adults is rarely explained by one mechanism. Medication effects, depression, dentition, taste changes, chronic disease, and social factors all contribute alongside any endocannabinoid signaling.

This trial suggests that a single dose of a THC/CBD product is not a reliable quick fix for the appetite-hormone piece of that puzzle, which supports keeping cannabis as one option among a broader geriatric nutrition assessment rather than a first-line hormonal therapy.

Lens takeaway
Treat appetite loss in older adults as multifactorial, not a single-mechanism problem Sativex alone will fix.

#### GLP-1 and Ghrelin Did Not Move as Hypothesized

The biological rationale for testing Sativex here was sound: GLP-1 and ghrelin are established appetite-regulating hormones, and THC has plausible endocannabinoid-mediated effects on both.

In this trial, however, neither hormone changed significantly after a single dose compared with placebo, and the dose-response relationship between plasma THC and these hormones also did not reach significance, which argues against a simple, easily detectable single-dose hormonal mechanism in this population.

Lens takeaway
The proposed GLP-1/ghrelin mechanism was not confirmed at a single-dose level in this trial.

#### Manage Expectations Before Recommending Sativex for Appetite

Clinicians considering Sativex specifically for appetite stimulation in older, frail patients should know that the best available randomized evidence in this population did not find a significant hormonal or subjective appetite effect from a single dose.

That does not mean the medication has no role in appropriate patients, but it argues against presenting appetite stimulation as an established, mechanism-confirmed benefit when counseling this age group.

Lens takeaway
Frame Sativex for appetite as unproven in older adults, not as an established indication.

#### Small Samples Cut Both Ways

A skeptical reader should notice that 17 participants is a small trial, and small trials can miss real effects just as easily as they can produce false positives.

The wide confidence intervals here, some of which come close to but do not cross into statistical significance, mean this result should temper enthusiasm without being treated as a closed case.

Lens takeaway
Hold this result with appropriate uncertainty rather than treating it as definitive in either direction.

#### Appetite Loss in Aging Populations Remains a Real Problem

Poor appetite and malnutrition risk in older adults is a meaningful public-health concern, and there is understandable interest in low-risk pharmacologic options.

This trial is a reminder that promising biological rationale does not automatically translate into a measurable population-level benefit, and that rigorous testing in the specific population of interest, here older adults rather than cancer or HIV patients, is necessary before broad recommendations are made.

Lens takeaway
Extrapolating cannabis appetite effects across populations without population-specific testing is risky.

#### Multiple Comparisons and a Secondary Analysis Design

This was a protocolized secondary analysis of a larger crossover trial, and the investigators appropriately applied Bonferroni correction across multiple comparisons, which is a methodological strength but also makes it harder to reach significance with a small sample.

Readers should also note this measured only a single dose rather than sustained dosing, which limits what can be concluded about real-world, repeated-use appetite effects.

Lens takeaway
Rigorous statistical correction plus a small, single-dose sample explains why a plausible effect did not reach significance.

#### What Would Strengthen This Evidence

A larger, adequately powered trial in older adults with poor appetite, ideally with repeated dosing over days to weeks and longer-term outcomes like weight and nutritional status, would help clarify whether a real but modest effect exists.

Until that evidence exists, this trial stands as a careful, well-designed but underpowered null result rather than a final answer about Sativex and appetite hormones in aging.

Lens takeaway
The next step is a larger, longer trial, not a change in clinical practice based on this result alone.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

[Leave a Message](https://cedclinic.com/contact/)
[Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
[Medical Consulting](https://cedclinic.com/book/)
[Cannabis Care](https://cedclinic.com/book/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Share this Evidence Watch

[X](https://twitter.com/intent/tweet?text=Sativex+and+Appetite+Hormones+in+Older+Adults%3A+What+a+New+Randomized+Trial+Found&url=https%3A%2F%2Fcedclinic.com%2Fsativex-appetite-hormones-older-adults-rct%2F)
[LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fsativex-appetite-hormones-older-adults-rct%2F)
[BlueSky](https://bsky.app/intent/compose?text=Sativex+and+Appetite+Hormones+in+Older+Adults%3A+What+a+New+Randomized+Trial+Found%20https%3A%2F%2Fcedclinic.com%2Fsativex-appetite-hormones-older-adults-rct%2F)
[Instagram](https://www.instagram.com/drcaplan/)
[Substack](https://doctorapprovedcannabis.substack.com/)
[RSS](https://cedclinic.com/feed/)

Source: [Effects of Sativex® Versus Placebo on Glucagon-like Peptide-1, Total Ghrelin, and Subjective Appetite in Older Adults with Poor Appetite: A Protocolized Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Crossover Trial.](https://pubmed.ncbi.nlm.nih.gov/42514343/)

Related Reading at CED Clinic
Continue exploring the evidence

[CBD Increases Food Intake in Controlled Human Trial](https://cedclinic.com/cbd-appetite-regulation-increased-food-intake-study/)

An earlier CED post on a controlled human trial showing CBD increased food intake despite lower ghrelin levels, useful context for comparing [cannabinoid effects](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) on appetite hormones across different THC/CBD formulations.

[Read the CBD appetite trial coverage](https://cedclinic.com/cbd-appetite-regulation-increased-food-intake-study/)

[How does CBD’s interaction with anandamide receptors affect appetite regulation?](https://cedclinic.com/how-does-cbds-interaction-with-anandamide-receptors-affect-appetite-regulation/)
Background on the endocannabinoid mechanisms proposed to link cannabinoids to appetite regulation, relevant for understanding why GLP-1 and ghrelin were tested in this trial.

[Read the mechanism context](https://cedclinic.com/how-does-cbds-interaction-with-anandamide-receptors-affect-appetite-regulation/)

[What Cannabis Safety in Hospice Care Requires](https://cedclinic.com/cannabis-safety-hospice-care/)
A related CED guide on using cannabis-based medicines for appetite, comfort, and quality of life in older and seriously ill patients, relevant to counseling this population.

[Read the hospice care guidance](https://cedclinic.com/cannabis-safety-hospice-care/)

## Frequently Asked Questions

Did this trial find that Sativex improves appetite in older adults?

No. The trial found no statistically significant difference between Sativex and placebo in subjective appetite ratings or in the appetite hormones GLP-1 and total ghrelin.

What was Sativex compared with in this study?

Sativex was compared with placebo in a double-blind, randomized, crossover design, so each participant received both a Sativex dose and a placebo dose on separate study days.

How many people were in this trial?

The analysis included 17 adults age 65 or older with poor appetite.

What dose of Sativex was used?

Participants received a single dose containing 8.1 mg THC and 7.5 mg CBD.

What outcomes did the researchers measure?

They measured postprandial GLP-1 and total ghrelin after one dose and a standardized breakfast, and tracked subjective appetite using visual analog scales across two doses, breakfast, and an ad libitum lunch.

Did higher THC levels in the blood predict a bigger appetite effect?

Higher plasma THC and metabolite concentrations trended toward lower GLP-1 and subjective appetite and higher ghrelin, but none of these associations reached statistical significance.

Is this trial proof that cannabis-based medicines cannot help with appetite in older adults?

No. The trial is a well-designed but small negative result. It could not detect a statistically significant effect, but its size and wide confidence intervals mean it cannot rule out a real, modest effect either.

Was this trial registered?

Yes. It is registered at ClinicalTrials.gov (NCT05503147) and EudraCT (2021-002318-15).

Where was this study published?

It was published in Nutrients on July 11, 2026, as a protocolized secondary analysis of a double-blind, randomized, placebo-controlled crossover trial.

What is the most practical takeaway for clinicians?

Clinicians should not present Sativex as a proven hormonal appetite stimulant in older adults based on current evidence, and should set realistic expectations while continuing to evaluate poor appetite through a broader geriatric lens.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).